title: Polypoidal choroidal vasculopathy, diagnosis and management.
abstract: Polypoidal Choroidal Vasculopathy (PCV) was first identified in 1985. Initially considered to be rare, PCV is currently frequently diagnosed in patients of African and Asian descent. In Caucasians, PCV counts for 10% of cases of AMD, and for up to 85% of patients with hemorrhagic or exudative retinal pigment epithelial detachment. Although the clinical presentation can be suggestive, extensive investigation with the indispensable indocyanine green angiography, is required for confirmation of PCV. Treatment has to be considered in active disease threatening the macula. Photodynamic therapy with Verteporfin is required for closure of PCV complexes. Anti-VEGF treatment reduces associated macular edema.
authors.affiliation: Department of Ophthalmology, University Hospitals, Leuven, Belgium. greetcoppens@hotmail.com
authors.forename: G
authors.initials: G
authors.lastname: Coppens
authors.forename: L
authors.initials: L
authors.lastname: Spielberg
authors.forename: A
authors.initials: A
authors.lastname: Leys
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011127:Polyps / Q000175:diagnosis* / Q000188:drug therapy*; D011166:Porphyrins / Q000627:therapeutic use; D011379:Prognosis; D000069579:Ranibizumab; D035583:Rare Diseases; D041623:Tomography, Optical Coherence; D000077362:Verteporfin
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D000068258:Bevacizumab; D000069579:Ranibizumab